Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $250.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by Morgan Stanley from $164.00 to $250.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on ALNY. HC Wainwright reiterated a buy rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. BMO Capital Markets reiterated an outperform rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. Chardan Capital reiterated a buy rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. William Blair reiterated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Finally, StockNews.com upgraded Alnylam Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, April 29th. Eight analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $245.14.

Alnylam Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ ALNY opened at $247.00 on Tuesday. The business has a fifty day simple moving average of $157.89 and a 200 day simple moving average of $164.23. The firm has a market capitalization of $31.24 billion, a price-to-earnings ratio of -92.16 and a beta of 0.30. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the company posted ($1.40) earnings per share. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. On average, research analysts anticipate that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the transaction, the director now owns 8,436 shares in the company, valued at $1,253,589.60. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CMO Pushkal Garg sold 2,103 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the sale, the chief marketing officer now owns 15,609 shares of the company’s stock, valued at $3,605,522.91. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,357 shares of company stock worth $13,436,711. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Teachers Retirement System of The State of Kentucky raised its position in shares of Alnylam Pharmaceuticals by 8.1% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock worth $4,964,000 after purchasing an additional 2,500 shares during the period. Cetera Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $238,000. Burney Co. raised its position in shares of Alnylam Pharmaceuticals by 371.9% during the first quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock worth $4,044,000 after purchasing an additional 21,325 shares during the period. Swedbank AB acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $3,084,000. Finally, Plato Investment Management Ltd raised its position in Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 4,346 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.